Value Advisors
Long/short equity

ELOS: FDA Is On The Way; Re-Iterating Syneron Buy Recommendation And Target Of $18

As promised in our previous research report on Syneron (TICKER: ELOS), we have completed our research on the potential of its next block buster product: Ultrashape fat reduction device. Over the past month we have interviewed leading physicians in the aesthetics and fat reduction space, industry specific research firms, regulatory experts including FDA submissions professionals, and patients.

Having learned about the product, its history, and Syneron's excellent FDA track record, we have strong conviction that Syneron's Ultrashape will receive FDA clearance during 2014. Due to the combination of FDA approval, the US market demand for additional FDA approved fat reduction devices and the ease of use of Ultrashape for both physicians and patients, we firmly believe that Syneron's hidden...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details